Go to content Go to menu Go to search

Vivalis: Merial signed a new commercial license for the EB66® cell line

24 January 2011

  • version française

Vivalis, a biopharmaceutical company, announced, on 11th January 2011, that Merial Ltd, a world leader in the veterinary vaccine field, signed a new commercial license for the production of a veterinary vaccine using Vivalis' EB66® cell line in last December 2010.

Terms of the agreement were not disclosed.

Statement of Vivalis' co-managers

"We are very pleased that Merial Ltd signed this second commercial license. This new agreement confirms that the EB66® cell platform is a reference cell substrate for the industrial manufacture of viral vaccines.

It further evidences that the majority of our clients who enter into an evaluation license are pleased with the robustness, efficiency, and regulatory compliance of our EB66® cell line, and extend their rights to commercial uses.

Lastly, this represents a significant corporate achievement through reaching our objective of seven licenses signed in 2010 and exceeding our 2010 commercial agreement estimates of three executed licenses over the predicted target of two" said Franck Grimaud, CEO, and Majid Mehtali, CSO, comanagers of Vivalis.

About Merial

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,700 people and operates in more than 150 countries worldwide. Merial is the Animal Health subsidiary of sanofi-aventis.

Find out more

Vivalis is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. Based in Lyon (France), Vivalis was founded in 1999 by the Grimaud group (ca. 1,500 employees), a worldwide leader in animal genetic selection.

Vivalis has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Merck, CSL, Kaketsuken, Merial, Intervet, SAFC Biosciences. Vivalis is a member of the French Lyonbiopôle bio-clusters.